
World’s First AI Vaccine Trial Boosts Biotech Innovation Market Prospects
A vaccine candidate whose key antigen was created using artificial intelligence has completed its first human safety trial, researchers reported June 4, 2026. The Phase I study, conducted at clinical sites in the United Kingdom, showed the experimental vaccine was well tolerated and prompted immune responses against multiple coronaviruses in






























